Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)

To find the highest tolerable dose and recommended dose of PRAME-TCR-NK cells that can be given to participants with recurrent and/or refractory melanoma. The safety and tolerability of PRAME-TCR-NK cells will also be studied.

Trial Details

NCT ID

NCT06660420

Phase

PHASE1

Sponsor

M.D. Anderson Cancer Center

Status

RECRUITING

Cancer Type

Melanoma

Interventions

Cyclophosphamide
Fludarabine

Locations (sample)

Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

Participants must be 18 years or older.
Participants must be willing and able to provide informed consent.
Participants must have HLA A\*02:01.
Participants must have histologically documented locally advanced, unrespectable, or metastatic melanoma that is relapsed and/or refractory to immu…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →